Malignancy risk in Bethesda class IV thyroid nodules in an iodine deficient region.
Bethesda system
Indeterminate cytology
lobectomy
thyroidectomy
Journal
Gland surgery
ISSN: 2227-684X
Titre abrégé: Gland Surg
Pays: China (Republic : 1949- )
ID NLM: 101606638
Informations de publication
Date de publication:
31 Jul 2023
31 Jul 2023
Historique:
received:
26
08
2022
accepted:
17
04
2023
medline:
20
9
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
ppublish
Résumé
According to the latest guidelines, in patients with high-risk nodules with indeterminate cytology, diagnostic lobectomy should be the preferable surgical approach in the absence of factors that suggest a total thyroidectomy. This retrospective observational study has as its main aim the evaluation of the cases that underwent surgery, for Bethesda class IV nodules in our iodocarent geographical area. Particular attention was paid to carcinoma incidence, preoperative nodule size, histological characteristics of the neoplasm, surgical approach and eventual need of radiometabolic treatment. A total of 320 patients were included that underwent surgery for Bethesda IV nodules, between January 2010 and December 2020, at the General Surgical Clinic of the University Hospital of Parma, Italy. A total of 230 total thyroidectomies (71.9%) and 90 lobectomies (28.1%) were performed. Our data showed a strong impact of the 2015 ATA Guidelines on the surgical approach choice, with a progressive propensity towards a conservative approach and an increase of lobectomies from 7.2% to 41.5% after the new guidelines introduction. However, in our sample the percentage of lobectomies remains below 50%; this data is certainly influenced by the number of cases of multinodular pathology, often bilateral, in our geographical area. The nodules malignancy rate resulted 28.8%. Our data showed that increasing size correlated with an increasing malignancy rate (P<0.01), and follicular carcinomas were found to be larger than papillary carcinomas (P<0.001). A statistically significant correlation also emerged between nodule size increase and local/lymphovascular invasion (P<0.05). On the other hand, there was no statistically significant correlation between nodule size and multifocality, and between nodule size and presence of lymph node metastases. Out of the patients where it was possible to find this data, 66% underwent radioiodiometabolic treatment: 59% with papillary carcinoma, and 85% with follicular carcinoma. In patients with Bethesda IV thyroid nodules, diagnostic lobectomy should be the preferable surgical approach in absence of factors that suggest total thyroidectomy. In our opinion, total thyroidectomy remains the first choice in large nodules (≥4 cm) as these nodules have a high malignancy rate, greater local/lymphovascular invasion and a consequent frequent indication for post-operative radiometabolic treatment.
Sections du résumé
Background
UNASSIGNED
According to the latest guidelines, in patients with high-risk nodules with indeterminate cytology, diagnostic lobectomy should be the preferable surgical approach in the absence of factors that suggest a total thyroidectomy.
Methods
UNASSIGNED
This retrospective observational study has as its main aim the evaluation of the cases that underwent surgery, for Bethesda class IV nodules in our iodocarent geographical area. Particular attention was paid to carcinoma incidence, preoperative nodule size, histological characteristics of the neoplasm, surgical approach and eventual need of radiometabolic treatment. A total of 320 patients were included that underwent surgery for Bethesda IV nodules, between January 2010 and December 2020, at the General Surgical Clinic of the University Hospital of Parma, Italy.
Results
UNASSIGNED
A total of 230 total thyroidectomies (71.9%) and 90 lobectomies (28.1%) were performed. Our data showed a strong impact of the 2015 ATA Guidelines on the surgical approach choice, with a progressive propensity towards a conservative approach and an increase of lobectomies from 7.2% to 41.5% after the new guidelines introduction. However, in our sample the percentage of lobectomies remains below 50%; this data is certainly influenced by the number of cases of multinodular pathology, often bilateral, in our geographical area. The nodules malignancy rate resulted 28.8%. Our data showed that increasing size correlated with an increasing malignancy rate (P<0.01), and follicular carcinomas were found to be larger than papillary carcinomas (P<0.001). A statistically significant correlation also emerged between nodule size increase and local/lymphovascular invasion (P<0.05). On the other hand, there was no statistically significant correlation between nodule size and multifocality, and between nodule size and presence of lymph node metastases. Out of the patients where it was possible to find this data, 66% underwent radioiodiometabolic treatment: 59% with papillary carcinoma, and 85% with follicular carcinoma.
Conclusions
UNASSIGNED
In patients with Bethesda IV thyroid nodules, diagnostic lobectomy should be the preferable surgical approach in absence of factors that suggest total thyroidectomy. In our opinion, total thyroidectomy remains the first choice in large nodules (≥4 cm) as these nodules have a high malignancy rate, greater local/lymphovascular invasion and a consequent frequent indication for post-operative radiometabolic treatment.
Identifiants
pubmed: 37727346
doi: 10.21037/gs-22-491
pii: gs-12-07-884
pmc: PMC10506119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
884-893Commentaires et corrections
Type : CommentIn
Informations de copyright
2023 Gland Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-22-491/coif). The authors have no conflicts of interest to declare.
Références
Cancers (Basel). 2022 May 17;14(10):
pubmed: 35626075
J Clin Endocrinol Metab. 2013 Feb;98(2):564-70
pubmed: 23275525
Ultraschall Med. 2013 Jun;34(3):238-53
pubmed: 23605169
Radiology. 2011 Sep;260(3):892-9
pubmed: 21771959
Updates Surg. 2021 Oct;73(5):1923-1930
pubmed: 34100186
Ann Oncol. 2019 Dec 1;30(12):1856-1883
pubmed: 31549998
ORL J Otorhinolaryngol Relat Spec. 2013;75(1):6-17
pubmed: 23486083
Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122
pubmed: 24989897
Gland Surg. 2016 Jun;5(3):295-9
pubmed: 27294036
Crit Rev Food Sci Nutr. 2021;61(1):25-59
pubmed: 31997660
Surgery. 2012 Apr;151(4):571-9
pubmed: 22001636
JAMA Otolaryngol Head Neck Surg. 2018 Sep 1;144(9):788-795
pubmed: 30027226
Tumori. 2015 Mar-Apr;101(2):144-7
pubmed: 25791536
Surgery. 2009 Oct;146(4):554-8; discussion 558-60
pubmed: 19789012
Ann Ital Chir. 2014 Jan-Feb;85(1):28-32
pubmed: 24755903
Ann Surg Oncol. 2014 Nov;21(12):3844-52
pubmed: 24943236
Gland Surg. 2016 Jun;5(3):312-7
pubmed: 27294039
Thyroid. 2012 Dec;22(12):1251-6
pubmed: 22962940
Endocr Pract. 2017 Apr 2;23(4):442-450
pubmed: 28095042
Surg Endosc. 2016 Jun;30(6):2489-95
pubmed: 26335076
BMC Endocr Disord. 2020 Apr 15;20(1):48
pubmed: 32293401
Thyroid. 2017 Apr;27(4):481-483
pubmed: 28114862
Arch Otolaryngol Head Neck Surg. 2010 Nov;136(11):1055-61
pubmed: 21079156
Best Pract Res Clin Endocrinol Metab. 2010 Feb;24(1):13-27
pubmed: 20172467
Gland Surg. 2019 Aug;8(Suppl 2):S105-S111
pubmed: 31475097
Langenbecks Arch Surg. 2010 Apr;395(4):323-6
pubmed: 20155496
Medicine (Baltimore). 2017 May;96(20):e6734
pubmed: 28514290
Eur J Surg Oncol. 2003 Nov;29(9):747-9
pubmed: 14602494
World J Surg. 2008 May;32(5):702-7
pubmed: 18224463
Thyroid. 2017 Nov;27(11):1341-1346
pubmed: 29091573
Surgery. 2008 Dec;144(6):1062-8; discussion 1068-9
pubmed: 19041019
Eur Thyroid J. 2017 Sep;6(5):225-237
pubmed: 29167761
Gland Surg. 2020 Jan;9(Suppl 1):S1-S5
pubmed: 32055492
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Int J Surg. 2017 May;41 Suppl 1:S21-S25
pubmed: 28506409